Application:
- Antibiotics can be envisioned as detailed blueprints, each representing a natural pharmacophore family with distinct structural features and activity profiles.
- Traditional methods of antibiotic discovery, relying on natural products or incremental modifications of existing drugs, have reached a plateau.
- There is an urgent need for new structural paradigms designed to circumvent bacterial resistance mechanisms.
Our innovation:
- By leveraging structural similarity between antibiotic families, we introduce Conflubiotics: a novel class of antibiotics synthesized through the precise fusion of pharmacophores from different antibiotic families.
- These innovative compounds are designed to overcome bacterial resistance by creating entirely new molecular architectures.
- Our proprietary blueprint database catalogs the structural and functional elements of over 300 natural antibiotics, acting as a toolkit for identifying compatible pharmacophores and designing hybrid antibiotics.
- Guided by the blueprint framework, we integrate pharmacophores from distinct antibiotic families via their shared functional groups.
- This rational design preserves the critical activity of each pharmacophore while producing molecules that bacteria have never encountered.
- A functional matrix maps potential pharmacophore combinations, enabling systematic and efficient exploration of fusion possibilities.
- This approach accelerates the discovery of antibiotics with unique modes of action and broad-spectrum efficacy.
Advantages
- Resistance Avoidance: Novel structures disrupt established resistance pathways, providing fresh therapeutic options.
- Rational Innovation: The blueprint-guided fusion process ensures compatibility and synergy between pharmacophoric elements, yielding structurally and functionally distinct antibiotics.
- Scalability: The systematic design framework allows rapid development of a diverse library of Conflubiotics targeting a wide range of bacterial infections.
Opportunity:
We are seeking collaboration with pharmaceutical and biotechnology companies to advance Conflubiotics toward clinical development.
Contact in Yissum: Ariela Markel
